Peptide therapy TikTok claims vs. what the research shows

What's this video probably claiming?

Accounts like @enhanced_hub typically run through a peptide stack lineup, usually hitting BPC-157 for gut and tissue repair, TB-500 for recovery, CJC-1295 paired with ipamorelin for growth hormone pulses, and GHK-Cu for skin and collagen. MK-677, despite not being a peptide in the traditional sense, gets lumped in here constantly because it produces similar GH-adjacent effects. The pitch is usually some version of: these compounds accelerate healing, rebuild joints, improve sleep, and optimize your body in ways that pharmaceuticals and supplements can't touch. The framing is almost always "biohacking" or "optimization," not medicine. Selank and semax get positioned as nootropic add-ons. The confidence level in these videos rarely matches the evidence level in the studies. That gap is the whole problem.

What does the science actually show?

Let's be honest about what we actually have. BPC-157 has a real animal literature, mostly rats, showing accelerated tendon healing and gastroprotective effects. Sikiric et al. have published extensively on this, including a 2018 review in Current Pharmaceutical Design, but human trials are essentially nonexistent as of 2024. TB-500, a synthetic fragment of thymosin beta-4, showed some cardiac repair signals in a phase II trial by Goldstein et al. (2012, Circulation), but that was IV administration in acute myocardial infarction patients, not subcutaneous peptide injections for gym recovery. CJC-1295 with DAC increases IGF-1 levels; Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) confirmed this in healthy adults at 1-3 mcg/kg doses, but the clinical outcomes data beyond IGF-1 elevation is thin. Ipamorelin is cleaner than older GHRPs in terms of cortisol and prolactin side effects, but long-term human safety data simply does not exist.

Where does the social media noise diverge from clinical reality?

The biggest distortion is the animal-to-human leap. A peptide healing a rat's Achilles tendon at a dose extrapolated to 200 mcg twice daily in a controlled lab environment is not the same as a human injecting compounded BPC-157 sourced from a peptide vendor. Compounding quality matters enormously. A 2023 analysis by Garrison et al. in JAMA found significant potency and sterility inconsistencies in compounded injectable peptides tested from online sources. MK-677 is frequently presented as a safe GH secretagogue alternative, but the AGHD trials (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism) showed insulin resistance as a real dose-dependent concern at 25 mg/day in older adults. Semax and selank have a small Russian clinical literature, mostly pre-2010 and not replicated in Western peer review. Calling them proven nootropics is a stretch that the actual data doesn't support.

What should you actually know?

Peptide therapy is a real clinical field, but it's early-stage for most of these compounds in humans. The FDA has not approved BPC-157, TB-500, or most of these peptides for any indication. In 2023, the FDA added BPC-157 to its list of drugs that cannot be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which means legal access through regulated telehealth has become significantly more constrained. GHK-Cu in topical form is better studied than its injectable version and carries less regulatory risk. Anyone presenting a peptide stack as a straightforward wellness protocol is glossing over real unknowns: long-term receptor desensitization, pituitary axis suppression with chronic GHRH analogs, and the absence of pharmacovigilance data. If you're considering any of this, those conversations belong with a licensed prescriber who has reviewed your labs, not a TikTok comment section.